TECENTRIQ (Roche Products Pty Ltd)
Product name
TECENTRIQ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
230 (255 working days)
Active ingredients
atezolizumab
Registration type
EOI
Indication
TECENTRIQ as monotherapy is now also indicated as adjuvant treatment following complete resection and no progression after platinum-based adjuvant chemotherapy for adult patients with stage II to IIIA (as per 7th edition of the UICC/AJCC staging system) NSCLC whose tumours have PD-L1 expression on ? 50% of tumour cells.